Applications

Clinical-Microbiomics provides world-leading end-to-end microbiome research services within human, animal and plant / soil microbiomes. Within the human microbiome, our team has extensive experience and are experts in the involvement of the microbiome in pre- and probiotic treatment and a vast array of clinical indications, including diabetes, insulin resistance, obesity, skin disease, IBD and IBS. Within animal and plant / soil microbiome, our team benefits from vast experience with difficult-to-handle samples and employment of metagenomics to understand potential microbial impacts on crops and livestock.

Over the past decade our knowledge about the human microbiome has increased dramatically. Associations have been found between specific community compositions, pathway configurations, and pathway expression levels and diseases including metabolic, autoimmune and inflammatory diseases.

Furthermore, causal relationships have been established between specific microbiome architectures and diseases such as obesity. Notably, a variety of drugs spanning several chemical classes have the potential to modulate dramatically the microbiome and the microbiome has shown to be capable of modulating drug degradation and adsorption.

While microbiome research is still in its infancy it promises to deliver:

  • New targets for medical intervention - e.g. microbiome targeting drugs.
  • Biomarkers for patient segmentation - e.g. dispositions for development of type 2 diabetes
  • New treatment strategies - e.g. fecal transplants for treatment of recurrent C. difficile infections.

Clinical-Microbiomics delivers a full range of microbiome characterizations in order to facilitate the study of the microbiome during pre-clinical and clinical studies. Examples of studies that can benefit from the services of Clinical-Microbiomics:

  • Comparative studies of disease states: Microbiome community composition has been linked with a wealth of different diseases and has in many cases also shown to be a casual factor. Gaining insight into such associations will help in understanding and, ultimately, treating disease. Clinical-Microbiomics can help you discover and evaluate such links.
  • Patient segmentation: Based on pre-clinical studies or early clinical studies biomarkers that are predictive of treatment outcomes can be identified. In full scale clinical trials patient segmentation or inclusion/exclusion can be based on the assessment of these markers. Clinical-Microbiomics can develop rapid tests for such microbiome markers.
  • Monitor effect of drugs on microbiome: Given the potentially large impact of the microbiome on the health state of humans it is vital to understand how the microbiome is perturbed by medicines under development. Clinical-Microbiomics can assist customers in those studies ranging from tens of patients to thousands of patients.
  • Development of probiotics, prebiotics and microbiome therapeutics: The microbiome is a therapeutic target and an increasing number of interventions are focused on shifting the microbiota composition towards a particular configuration. Clinical-Microbiomics can deliver high quality microbiome analysis from clinical trial samples to support microbiome modulation.